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Abstract
Cardiovascular disease remains the leading cause of mortality in the Westernised world. Lifestyle changes and drug therapy 
can reduce cardiovascular risk. Many interventions such as lipid-lowering therapy reduce relative risk to the same extent 
irrespective of baseline risk, but the absolute benefit is still highest in those with the highest absolute risk. Cardiovascular risk 
assessment is a tool to determine absolute cardiovascular risk in asymptomatic patients and to select those most likely to 
benefit from intervention. Conventional risk assessment (Framingham) requires age, gender, blood pressure, smoking status, 
total cholesterol and high-density lipoprotein cholesterol (HDLC) to determine risk. This is usually expressed as the 10-year 
risk of coronary heart disease. The accuracy and predictive ability of conventional risk assessment have limitations. Many 
biomarkers, genetic tests and vascular imaging procedures correlate statistically with vascular risk. Adding these tests to 
conventional risk assessment (expanded risk assessment) may therefore improve our ability to predict risk. It has, however, 
been difficult to conclusively demonstrate that expanded risk assessment outperforms conventional risk assessment. Many 
tests and procedures require further validation before they become part of routine clinical practice. Additional testing may 
be useful in patients with intermediate risk or where risk is difficult to determine for other reasons. 
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Prediction is very difficult, especially if it’s about the future
(Niels Bohr, Danish physicist) 
Introduction
Cardiovascular disease remains the most common cause 
of death in the Westernised world, accounting for 43.8% of 
male deaths and 57% of female deaths in the World Health 
Organization (WHO) European region in 2004.1 The risk of 
cardiovascular death can be reduced by both lifestyle (e.g. 
smoking cessation, dietary changes and exercise) and 
pharmacological interventions (e.g. lipid-modifying drugs 
and treatment of hypertension). For patients to benefit 
optimally, these interventions should ideally be started long 
before cardiovascular disease is clinically overt. Primary 
prevention of cardiovascular disease thus often involves 
asking people with no symptoms of cardiovascular disease 
to change their lifestyle and to take medication for the rest 
of their lives. Such interventions are clearly associated with 
costs. Medication, laboratory monitoring and doctor’s visits 
cost money, while there are also potential psychological 
costs associated with the transition from a state of 
perceived health to being a ‘patient’ taking daily medication. 
(See Spence2 for an interesting critique of current medical 
practice.) 
Cardiovascular risk assessment is a tool used to select 
patients for ‘intervention’. For many interventions, the 
relative risk reduction achieved is independent of baseline 
risk, but interventions are primarily targeted at those with 
the highest absolute risk, as these patients stand to gain the 
most in absolute risk reduction. The intensity and number of 
interventions recommended rise with the risk. 
Clearly, cardiovascular risk assessment does involve ‘trying 
to predict the future’, and it is thus not surprising that it is 
neither very exact nor free of problems. This article deals 
with risk assessment in the primary prevention setting. 
Patients with established cardiovascular disease and type 2 
diabetes mellitus should not be risk-scored for primary 
prevention. There are tools to assess future risk in those 
with established cardiovascular disease and type 2 diabetes 
mellitus; however, these are not discussed here. 
Cardiovascular risk 
Cardiovascular risk is determined by the interaction of many 
different risk factors. Some factors increase risk, while 
others are protective. In the individual, cardiovascular risk 
is determined by the balance of these opposing forces. Risk 
may be high because of a single dominant force (a markedly 
elevated risk factor such as very high low-density lipoprotein 
cholesterol [LDLC] in familial hypercholesterolaemia), or 
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multiple individually moderately deleterious risk factors 
(e.g. moderately high LDLC, low high-density lipoprotein 
cholesterol [HDLC] and mild hypertension) may combine to 
elevate risk significantly. 
The INTERHEART study was a case-control study of risk 
factors for myocardial infarction in 52 countries.3 It showed 
that, although the relative prevalence of risk factors differed 
geographically, for example, smoking rates were lower 
in more developed countries, the effect of the studied 
risk factors was consistent across geographic regions, 
ethnic groups and gender. More than 90% of observed 
risk was explained by nine modifiable risk factors (Table 
I).3 Conventional risk assessment does not utilise all the 
INTERHEART risk factors and data collection is generally 
limited to lipid and demographic variables, blood pressure 
and smoking status. Conventional risk assessment does 
include age and gender – these variables were adjusted for in 
the INTERHEART study, but they were not further analysed, 
as they are non-modifiable risk factors. In conventional 
risk assessment, age and gender are, however, crucial 
variables. Age in particular is a very strong determinant of 
absolute cardiovascular risk and is the dominant risk force 
in older people.
Conventional risk assessment
The Framingham algorithm4 is probably the best-known 
risk-assessment tool, but alternative risk scores are 
available. Some of the better known risk scores include the 
European SCORE project,5 which was derived from a large 
database of prospective European studies; the PROCAM 
Score6 from Germany; and the QRisk Score,7,8 derived 
from a general practitioner database in Britain. Apart 
from QRisk, all scores were derived in a similar fashion. 
Multiple clinical variables are documented in a population 
of individuals free of clinical cardiovascular disease. These 
individuals are then prospectively followed up over many 
years and all cardiovascular events are documented. The 
data set is then analysed to identify clinical variables (risk 
factors) associated with cardiovascular outcomes. With this 
information, a statistical model is developed that attempts 
to predict the measured outcome based on clinical variables 
documented at study entry. The final product is a complex 
mathematical risk model and equation. Risk equations 
are cumbersome and difficult to work with and thus are 
not routinely used in clinical practice. Instead, clinicians 
generally use tables derived from the risk equation, but 
many online risk calculators are now available that utilise 
risk equations (See www.chd-taskforce.com). The current 
Framingham tables for South Africa can be found at the end 
of the article.
Although the principles underlying all risk models are 
the same, there are some important, clinically relevant 
differences between them. Age, gender and smoking 
status are common input variables, but the Framingham 
Score, for instance, uses total cholesterol and HDLC 
values as lipid values, while PROCAM uses HDLC, LDLC 
and triglycerides and SCORE only uses total cholesterol. 
QRisk includes social deprivation as a risk factor. Because 
treatment decisions are often based on the final derived 
risk, it is important to know what risk is being calculated 
and what the risk threshold in local guidelines refers to. The 
best-known version of the Framingham Score estimates 
the 10-year risk of hard coronary endpoints (myocardial 
infarction, coronary death), while SCORE calculates 10-
year cardiovascular mortality. It is thus not surprising that 
European guidelines based on the SCORE risk recommend 
intervention when risk is more than 5%, while guidelines 
based on Framingham have a threshold of 20%.
Box 1 illustrates how risk assessment may be used in 
practice. 
Absolute and relative risk 
Most risk-assessment tools report the absolute 10-year 
risk. A low short-term absolute risk may sometimes mask 
high long-term risk. The 10-year risk for a young patient 
with multiple risk factors may for instance be 3%, which 
does not appear particularly high. However, the risk for age-
matched peers without additional risk factors is likely to be 
less than 1%. These patients would be falsely reassured if 
told there is no cause for concern. The risk of myocardial 
infarction will remain low for the next few years, but could 
be substantial by middle age. These patients should thus be 
informed of the increased long-term risk and risk reduction 
should be started. This need not necessarily be drug 
therapy, but could initially be lifestyle advice. 
Table I: Risk factors for myocardial infarction identified in the 
INTERHEART study
Risk factor Odds ratio (99% CI)a PARb (99% CI)
Current and former smokingc 2.04 (1.86–2.25) 35.7% (32.5–39.1)
Diabetes 2.37 (2.07–2.71) 9.9% (8.5–11.5) 
Hypertension 1.91 (1.74–2.10) 17.9% (15.7–20.4)
Abdominal obesity 
(top tertile vs bottom tertile)
1.62 (1.45–1.80) 20.1% (15.3–26.0)
Psychosocial stressd 2.67 (2.21–3.22) 32.5% (25.1–40.8)
Daily vegetables and fruite 0.70 (0.62–0.79) 13.7% (9.9–18.6)
Exercisee 0.86 (0.76–0.97) 12.2% (5.5–25.1)
Alcohol intakee, f 0.91 (0.82–1.02) 6.7% (2.0–20.2)
ApoB/ApoA-I ratio (top 
quintile vs bottom quintile)f
3.25 (2.81–3.76) 49.2% (43.8–54.5)
a. The odds ratio is fully adjusted for all additional risk factors
b. PAR: Population attributable risk. This is calculated as the risk attributable to a risk factor 
(e.g. risk of lung cancer in smokers minus the risk in non-smokers) multiplied by the 
prevalence of exposure of the population to the risk factor (e.g. percentage of population 
that smokes). The PAR therefore measures the potential impact on a population if one were 
to eliminate the risk factor completely (e.g. reduction in lung cancer if everybody stops 
smoking). The PAR presented here is fully adjusted for all other risk factors. 
c. The risk is compared to that in never-smokers. 
d. Defined as an index of positive exposure to depression, perceived stress at home and work, 
low locus of control and major life events and referenced to non-exposure to all five risk 
factors. 
e. These factors are protective, as reflected in the odds ratio less than one. The PAR is that in 
the group without the protective exposure. 
f. Alcohol intake was defined as the regular consumption of alcoholic beverages more than 
three times a week. 
Table adapted from Yusuf et al.3
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The SCORE algorithm uses relative risk to identify young 
patients with high long-term risk. Relative risk is the 
patient’s risk compared to age-matched peers with optimal 
risk factors. The Framingham study group has developed 
a lifetime risk calculator based on long-term follow-up of 
their initial cohort.9 Alternatively, one can use the standard 
Framingham algorithm and project risk to age 60. 
Problems with risk assessment
Prevention strategies
Current primary prevention strategies suggest drug therapy 
for patients with high short-term (10-year) absolute risk. 
The aim is to prevent as many cardiovascular events as 
possible, while keeping the number of treated patients as 
small as possible. This strategy provides the ‘most bang 
for the buck’ in the short term, but many events remain 
unprevented for the following reasons. Prevention reduces, 
but does not abolish, risk in those offered therapy. The 
majority of the population will be classified as low risk and 
not offered treatment. However, a low event rate in a large 
population contributes many events to the final event tally. 
Using data from the PROCAM study, Assmann estimates 
that 80% of the male population aged 35 to 65 is at low risk 
(mean 10-year risk 3%), 14% is at intermediate risk (mean 
10-year risk 13%) and 6% is at high risk (mean 10-year risk 
33%). Thirty-two per cent of all myocardial infarctions will 
occur in the low-risk group, 35% in the intermediate-risk 
group and 33% in the high-risk group.10 Were one to offer 
20% of the population treatment (high and intermediate 
risk), approximately one-third of all patients with myocardial 
infarction would not have had the chance to benefit from 
preventative treatment. This has led some to suggest that 
a universal prevention strategy using a ‘poly-pill’ would be 
more effective. The ingredients of the poly-pill would include 
several low-dose antihypertensives, a statin and folic acid. 
The poly-pill would be prescribed to everybody once they 
reach a certain age, irrespective of blood pressure or lipid 
levels.11 There has been much debate about the poly-pill 
strategy, as it ‘medicalises’ the entire population. A more 
appealing strategy is to reduce risk factors at a population 
level by population level interventions (e.g. tobacco 
legislation, reducing salt in processed foods and creating 
urban environments conducive to walking) and then 
targeting drug interventions at selected high-risk individuals. 
Epidemiology
Cardiovascular disease rates differ substantially among 
populations, and equations derived in one population 
may not be directly transferable to other populations. 
The Framingham equation can be calibrated for non-USA 
populations with the aid of local cardiovascular disease 
Example 1
Mr Smith is 43 years old. He comes in for a general check-up, but 
you soon realise that his main concern is his risk of coronary heart 
disease, as a colleague of his died suddenly during a board meeting 
a week ago. You obtain the following additional information:
• Smoker of 20 cigarettes a day for the last five years.
• Blood pressure 114/70 mmHg on no treatment.
• Total cholesterol: 3.9 mmol/L; HDLC: 1.9 mmol/L.
• Fasting glucose: 4.1 mmol/L.
You calculate his Framingham risk at 1% for the next 10 years.
The only intervention you recommend is smoking cessation, 
maintaining a healthy diet and regular exercise. He wants to know 
why you did not request an hsCRP (“All my friends’ doctors do it”) 
and whether he should not go for the ‘heart scan test’. You explain 
that his risk is low and further investigations are very unlikely to 
reclassify risk as high. You explain that a study of CAC scoring did 
show that patients with high CAC and low Framingham scores had 
higher observed event rates than those in whom both scores were 
low. However, the absolute event rate in those with high CAC and 
low Framingham scores was still in the low-risk range. 
Example 2
Mrs Potgieter is 32 years old and had a lipid test, as she is applying 
for life insurance. The total cholesterol was 9.3 mmol/L, with an 
HDLC of 1.4 mmol/L and LDLC of 7.5 mmol/L. The BP is 124/80 
mmHg on no treatment and she has never smoked. She grew up 
in an orphanage because her mother died during childbirth and her 
father had a fatal myocardial infarction at age 33. You palpate a 
small nodule in her left Achilles tendon. 
You apply for funding of statin therapy from her medical aid, but the 
application is declined because the Framingham risk is less than 
1% for the next 10 years. 
This patient clearly has the phenotype of familial hyper-
cholesterolaemia and should not be risk-scored. Framingham 
grossly underestimates her risk and she should receive treatment 
irrespective of the calculated risk. Do not forget to make sure she is 
taking adequate contraception before starting the statin. 
Example 3
Mr Douglas is 52 years old, and would like your opinion on his 
lipids. His wife is nagging him “to do something”, but he says 
that his lipids are “not really that high”.  You obtain the following 
additional information:
• Smoker of 10 cigarettes a day for 20 years.
• Blood pressure “just a bit high” at 148/93 mmHg, despite 
treatment.
• Total cholesterol: 5.7 mmol/L; HDLC 0.8 mmol/L.
You calculate his Framingham risk. It is 25%, even though none 
of his values is “shockingly high”, as he puts it. You use the risk 
calculation to explain how multiple factors are combining to create 
high absolute risk and to justify the need for lifestyle and drug 
intervention. 
Box 1: Risk assessment in practice
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statistics. The SCORE algorithm divides Europe into high-
risk countries (e.g. Germany and the United Kingdom) and 
low-risk countries (e.g. France and Italy) with separate 
charts. South Africa does not have sufficiently accurate 
cardiovascular data to allow accurate algorithm calibration 
and our very diverse population further complicates the 
matter. South African guidelines thus currently recommend 
the use of the unmodified Framingham equation. 
Cardiovascular disease rates also change with time and it 
is important to adjust algorithms accordingly. Unmodified 
algorithms over-predict events in countries with declining 
cardiovascular disease rates. 
Statistical issues
Risk prediction operates at a population and not at an 
individual level. A 5% 10-year risk turns into a ‘100% risk’ 
for the individual who does have the event. Unfortunately, 
we are not yet able to pinpoint risk at an individual level and 
provide truly personalised medicine. 
Risk charts categorise continuous variables such as total 
cholesterol. Small changes in a variable may move it from 
one category to the next, significantly altering the calculated 
risk. Online risk calculators use the original risk equation 
and are not affected by this problem. Algorithms also 
generally do not account for risk variables changing over 
time. Smoking, for instance, is generally classified as ‘Yes’ 
or ‘No’, with little regard to dose and duration. A person 
classified as a ‘non-smoker’ may have never smoked 
or might have smoked 40 cigarettes a day for 30 years 
before quitting and subsequently earning the ‘non-smoker’ 
classification a year later. 
The statistical models used to analyse the data generated 
from the study population have in general been fairly 
simplistic. More sophisticated analysis and modelling 
techniques such as neuronal network analysis may improve 
algorithm performance. 
Clinical issues
Risk algorithms were designed for patients with risk factors 
within the ‘usual range’ and do not cater for patients with 
markedly elevated risk factors. Framingham, for instance, 
allocates the same point score to all total cholesterol values 
> 7.2 mmol/L, but cholesterol readings of 7.3 mmol/L or 
20.0 mmol/L clearly have very different implications. 
Patients with genetic dyslipidaemias such as familial 
hypercholesterolaemia should thus not be risk-scored, as 
their risk will be severely underestimated.4;5
Because risk algorithms incorporate a limited number of 
variables, they may not be appropriate in all situations. 
Risk may for instance be increased by other non-measured 
factors such as renal dysfunction or chronic inflammation. 
Expanded risk assessment
Multiple alternative risk-prediction strategies have been 
explored in an effort to overcome the limitations of 
conventional risk prediction. The two main alternatives are 
adding further blood tests or evaluating the vasculature 
directly. The optimal expanded risk-assessment strategy 
has not been defined as yet and the literature on the topic 
is characterised by debate and controversy. Many authors 
hold strong views and strongly propagate their ‘favourite’ 
blood test or imaging modality. At times, it can be difficult to 
distinguish science from opinion and self-interest. 
One of the debates is on what the optimal statistical tests 
for evaluating new markers are. To be clinically useful, 
new markers must not only be statistically significantly 
associated with cardiovascular risk (all markers should meet 
this standard), but the addition of the information provided 
by the new risk marker to conventional risk assessment must 
significantly improve overall predictive ability. Of particular 
relevance is the ‘reclassification index’: how many patients 
will be correctly reclassified from one risk category (high risk, 
low risk and intermediate risk) to another. Reclassifications 
from intermediate risk are particularly relevant, as they often 
affect treatment decisions. A comprehensive review of all 
alternative strategies is beyond the scope of this article, and 
I only touch on a few points of particular relevance. 
Additional blood tests
Additional blood tests may include more detailed lipid 
testing, the measurement of other biomarkers or genetic 
testing. Of the additional lipid tests, apolipoproteinB100 
(apoB) and lipoprotein(a) are probably the best known. 
ApoB is a good marker of the number of atherogenic 
particles and some, but not all, studies show that it predicts 
risk better than LDLC.12-17 Elevated lipoprotein(a) (> 0.5 g/L) 
confers increased risk and may sway the decision towards 
treatment when risk is borderline. 
C-reactive protein
C-reactive protein (CRP) is the best studied and validated 
biomarker of vascular risk.18 The CRP test for risk prediction 
is known as high-sensitivity CRP (hsCRP). The ‘high 
sensitivity’ simply indicates that the assay can measure 
CRP in its normal physiological range. Initial CRP assays 
were designed to measure high levels of CRP, which may 
increase more than a thousand-fold above its baseline 
with acute inflammation. As inflammation is central to 
the pathogenesis of atherosclerosis, CRP as a marker of 
inflammatory activity has attracted considerable research 
interest. There is substantial evidence that elevated 
CRP correlates with increased cardiovascular risk.18 
There is, however, still debate about the clinical role of 
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hsCRP measurement in risk assessment. There are firmly 
entrenched ‘enthusiast’ and ‘sceptic’ camps in this regard.
One of the controversial issues is whether CRP is a risk 
marker or a risk factor. Assuming elevated CRP is a risk 
factor causally contributing to atherosclerosis, then 
agents that specifically lower CRP may be useful anti-
atherosclerotic drugs. In Mendelian randomisation studies, 
genetically elevated CRP (due to polymorphisms in the CRP 
gene) is not associated with an increased atherosclerosis 
risk19 and in an analysis of the PROVE-IT/TIMI22 study, on 
treatment, CRP correlated positively with the number of 
uncontrolled risk factors.16 Mice with high levels of human 
CRP, either following injection or expressed transgenically, 
also do not develop accelerated atherosclerosis.20 The 
balance of evidence therefore suggests that CRP marks 
rather than causes risk. 
The utility of adding CRP measurement to routine risk 
assessment is also not yet entirely clear. The Reynolds 
Risk Score is probably the best-known risk score 
that incorporates CRP. Adding CRP measurement to 
conventional risk assessment reclassified 20% of men with 
intermediate (10–20%) 10-year risk to another risk category, 
but adding family history was at least as predictive as CRP 
measurement.21 The utility of CRP in identifying patients 
that will benefit from statins for primary prevention has 
also never been rigorously tested. The often quoted Jupiter 
study22 enrolled patients with high CRP and relatively low 
LDLC. It showed that rosuvastatin 20 mg/day compared 
to placebo prevented cardiovascular events. The Jupiter 
study did, however, not enrol patients with low CRP and 
therefore did not test whether aggressively lowering lipids 
in patients with low CRP would be futile. Until further 
evidence becomes available, it is best to measure CRP only 
in selected patients with intermediate (10–20%) 10-year risk 
rather than requesting the test routinely. In intermediate-risk 
patients, a CRP of more than 2 mg/L would be a reasonable 
cut-off point for considering statin therapy for primary 
prevention.18 
Other biomarkers
Other potential non-traditional risk markers include fasting 
glucose, leukocyte count, homocysteine and lipoprotein-
associated phospholipase A2 (LP-PLA2), to name just a 
select few.23 A recent meta-analysis of studies of glucose 
and vascular risk showed that diabetes is associated with 
two-fold vascular risk. In fasting, non-diabetic patients, 
blood glucose concentrations higher than 5.6 mmol/L 
were modestly associated with vascular risk, but in the 
study statistical model addition of glucose information to 
conventional risk factors did not improve risk prediction.24 
This of course does not imply that one should not measure 
the fasting glucose (to diagnose diabetes and assess the 
risk of future diabetes) – simply that the measurement 
does not add powerfully to cardiovascular risk prediction 
if it is in the non-diabetic range. There is contradictory data 
on the utility of the leukocyte count and no information 
on whether it improves conventional risk prediction.23 
Homocysteine measurement is still requested fairly often, 
yet no study has assessed the value (risk reclassification) 
of adding homocysteine measurement to conventional 
Framingham assessment. As is the case for CRP, the 
majority of studies do show an epidemiological link between 
hyperhomocysteinaemia and vascular disease – there is just 
no evidence that this relationship can meaningfully improve 
risk prediction.23 Homocysteine intervention studies with 
B-group vitamin supplementation did lower homocysteine 
successfully, but did not improve cardiovascular 
outcomes.25 Correct specimen handling is also crucial in 
obtaining correct homocysteine measurements and delays 
between specimen collection and laboratory processing 
often cause spurious elevations. LP-PLA2 is a marker of 
vascular inflammation and is also being investigated as a 
novel therapeutic target. LP-PLA2 measurement has been 
proposed as an additional risk measure in intermediate-risk 
patients, but as yet no outcome studies support its use.26-28
Genetic testing
Single nucleotide polymorphisms in multiple genes 
associate with cardiovascular risk. Risk alleles were initially 
identified using the candidate gene approach (testing genes 
known to affect lipid metabolism or inflammation) and, more 
recently, by genome-wide association studies. Currently, 
further work is required to understand the impact of risk 
alleles singly and in combination and what they can add 
beyond conventional risk factors. Genetic testing may well 
become available in the future, but will require assessment 
of multiple single nucleotide polymorphisms (40 or more) 
using gene chip technology.29 None of the currently 
marketed genetic screening tests have been sufficiently 
validated to be used routinely. 
Vascular evaluation
Direct evaluation of the vasculature, usually by imaging, aims 
to detect subclinical atherosclerosis. Patients with evidence 
of vascular ‘damage’ are at higher cardiovascular risk. It 
is, however, important to note that one cannot extrapolate 
directly from vascular image to clinical event. Events can 
occur in those with little evident atherosclerosis (e.g. rupture 
of a small non-calcified plaque and vascular occlusion by 
thrombosis), while other patients with extensive plaques 
and vascular calcification may remain event-free. 
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Vascular evaluation assesses risk from another angle; 
it does not replace conventional risk evaluation, but 
can complement it in certain situations. Currently, it is 
most useful in those patients that were not adequately 
represented in the risk-derivation c ohorts, for instance 
those with ‘unusual’ risk factors such as very high HDLC, 
which may be proatherogenic in some and anti-atherogenic 
in others. Vascular imaging techniques are also frequently 
used in initial studies of novel anti-atherosclerotic agents. 
Only drugs that show positive effects in imaging studies 
proceed to large clinical outcome studies. 
Ankle-brachial index 
Ankle-brachial index (ABI) is non-invasive, relatively easy to 
measure and the equipment required is not very expensive. 
An ABI of less than 0.90 approximately doubles the 10-year 
total cardiovascular event rate, but once again, limited data 
are available on the clinical utility of routinely adding ABI 
measurement to cardiovascular risk assessment.30
Carotid intima media thickness 
Carotid intima media thickness (IMT) can be measured 
non-invasively using ultrasound. The average distance 
between the lumen-intima and the media-adventitia 
interfaces is measured over a segment of arterial wall. 
Carotid IMT increases in everyone with age, but excessive 
thickening is a marker of subclinical atherosclerosis and 
increased vascular risk.31 The value of carotid IMT in risk 
assessment has been shown in research settings, using 
highly standardised scanning and reading protocols. It has 
not been shown as yet that this precision can be replicated 
in non-research settings. Currently, many different protocols 
are used and reporting standards are also not uniform, 
and IMT may for instance be reported as either mean of 
mean or mean-maximum. Reference and cut-off values can 
therefore not simply be taken from published data without 
local protocol validation. Ideally, each unit should establish 
its own reference ranges. 
Currently, carotid IMT should not be performed routinely 
outside of research settings, but is a useful tool in individual 
patients with difficult-to-determine cardiovascular risk.23
Coronary artery calcium scoring
Coronary calcium can be measured rapidly and reliably with 
electron beam CT (EBCT). Coronary calcium is a marker 
of coronary atherosclerosis, though its presence does not 
necessarily imply luminal obstruction and its absence does 
not prove the arteries are disease-free. Multiple studies 
have shown that a coronary artery calcium (CAC) score 
of zero is associated with a very low risk of events in the 
medium term, while increasing scores are associated with 
a stepwise increase in the risk of events. Some studies 
have also shown that CAC scoring can provide additional 
risk information beyond that derived from conventional 
risk factors.31 There is as yet no evidence that a screening 
strategy based on CAC scoring is associated with improved 
clinical outcomes.23 EBCT is associated with a small but 
significant radiation exposure. If CAC is determined with 
conventional multidetector CT scanning, the radiation 
exposure is often higher. There is concern that routine use 
of CAC screening will lead to excessive further downstream 
investigations such as stress testing and angiography 
in asymptomatic patients. There is, however, very little 
evidence that interventions beyond optimal risk factor 
control improve the outcome of asymptomatic patients. 
Guidelines on CAC screening vary somewhat, but generally 
do not recommend routine CAC screening.32 CAC screening 
should only be considered in intermediate risk patients 
and when the patient and physician both understand the 
implications of the test.33 CT coronary angiography has not 
been evaluated in detail as a screening test and should thus 
not be used for the screening of asymptomatic patients. It 
is a diagnostic test for the evaluation of patients with clinical 
problems such as chest pain of unclear aetiology.32;34
Conclusion
Cardiovascular risk assessment is a science in rapid 
evolution. Exciting new biomarkers, genetic tests and 
imaging procedures enter the medical marketplace regularly 
and are often promoted enthusiastically for routine use. All 
of these tests correlate significantly with cardiovascular risk. 
What has been much more difficult to show is that adding 
the results of these tests to a conventionally derived risk 
estimate significantly improves predictive ability. Proving 
that the ‘expanded test package’ is better than the ‘standard 
package’ is difficult and often requires large and expensive 
studies. These studies do, however, need to be done, as 
routine implementation of certain strategies, for example 
routine vascular imaging of all adults over a certain age (as 
has been suggested)35 is associated with significant health 
care cost implications. Not all tests, for example carotid 
IMT scanning, have been sufficiently standardised to move 
from the research setting to routine clinical use, and many 
tests have not yet been validated in non-white populations. 
Routine clinical risk assessment is therefore still best done 
with conventional risk algorithms, despite the imperfections 
associated with this approach. Additional tests may be 
helpful when risk is borderline or when ‘unusual’ risk factors 
are present. 
CPD Article: Cardiovascular risk assessment CPD Article: Cardiovascular risk assessment





























20–39 40–49 50–59 60–69 70–79
< 4 0 0 0 0 0
4.1–5 4 3 2 1 0
5.1–6.2 7 5 3 1 0
6.21–7.2 9 6 4 2 1




20–39 40–49 50–59 60–69 70–79
< 4 0 0 0 0 0
4.1–5 4 3 2 1 1
5.1–6.2 8 6 4 2 1
6.21–7.2 11 8 5 3 2
≥ 7.2 13 10 7 4 2
Age (years)
20–39 40–49 50–59 60–69 70–79
Non-smoker 0 0 0 0 0
Smoker 8 5 3 1 1
20–39 40–49 50–59 60–69 70–79
Non-smoker 0 0 0 0 0
Smoker 9 7 4 2 1
Systolic BP (mmHg) If untreated If treated




≥ 160 2 3
Systolic BP (mmHg) If untreated If treated




≥ 160 4 6
Points total 10-year risk %
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> 25 ≥ 30
The 10-year risk for coronary disease is calculated by adding the points for age, total cholesterol, 
smoking status, HDLC and blood pressure. The risk can then be read from the points table. The 
Framingham calculation should not be used in patients with severe monogenic hyperlipidaemia 
(e.g. familial hypercholesterolaemia), diabetic patients and patients with clinically overt 
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